Inobrodib, Pomalidomide And Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Overview

Acerca de este estudio

The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.

Elegibilidad para participar

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

* Male or female ≥18 years of age
* Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy
* Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2
* Adequate hematological, renal and hepatic function
* Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners

Exclusion Criteria:

* Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest; any antibody based therapy within 30 days
* Prior treatment with p300/CBP bromodomain inhibitors
* Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide)
* Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment
* Major surgery within 4 weeks of the first dose of study treatment
* Live vaccine within 4 weeks of study treatment
* Active or unresolved adverse events
* Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma
* Female patients who are pregnant or breast-feeding at any time during the study
* Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data

Ubicaciones participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Ubicación de Mayo Clinic Estado Contacto

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Saurabh Chhabra, M.B.B.S., M.S.

Comunícate con nosotros para obtener los estados más recientes

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Sikander Ailawadhi, M.D.

Comunícate con nosotros para obtener los estados más recientes

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Investigador principal de Mayo Clinic

Shaji Kumar, M.D.

Comunícate con nosotros para obtener los estados más recientes

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available